Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly activated by mutation in non-small cell lung cancer. The mechanism of this oncogenic activation is not completely understood, but in contrast to that of the wildtype EGFR, it is proposed to be independent of kinase domain dimerization. Mechanistic studies on EGFR have mainly relied on cell-based assays or isolated kinase domain measurements. Here we show, using purified, near full-length human EGFR proteins (tEGFRs), that two oncogenic mutants are fully active independently of EGF and highly resistant to the therapeutic and endogenous inhibitors cetuximab, lapatinib and MIG6. Based on the pattern of inhibition and the effects of additional asymmetric kinase dimer interface mutations, we propose that these oncogenic EGFR mutants drive and strongly depend on the formation of the asymmetric kinase dimer for activation, which has implications for drug design and cancer treatment strategies.
a r t i c l e s
The epidermal growth factor receptor family comprises four members in humans: EGFR (HER1), HER2/Neu, HER3 and HER4 (ref. 1). These receptor tyrosine kinases (RTKs) have consequential roles in a variety of solid cancers and are the targets of many successful antineoplastic therapeutics 2,3 . The synthetic compound erlotinib targets the active conformation of the kinase domain and is clinically approved for treating non-small cell lung cancer. Erlotinib is particularly effective for cancers in which the EGFR kinase domain contains activating mutations, the two most common of which are ∆746-750 and L858R (refs. 4-7) . The synthetic compound lapatinib is FDA-approved for the treatment of HER2/Neu-positive breast cancer and is proposed to bind preferentially to the inactive conformations of EGFR and HER2/Neu 8, 9 kinase domains. Cetuximab is an antibody that binds to the EGFR ectodomain, blocking the binding of EGF to the receptor, and is approved for treatment of several EGFRpositive cancers 10, 11 .
EGFR family members are composed of a ligand-binding extracellular region, a membrane-spanning region, a juxtamembrane region, a kinase domain and a C-tail that can be autophosphorylated 12, 13 (Fig. 1a) . Activation of EGFR by EGF involves the formation of a specific dimer through the extracellular ligand-binding regions [14] [15] [16] [17] [18] , which seem to promote an asymmetric dimer interaction between the kinase domains, in which the activity of one kinase subunit (acceptor kinase) is stimulated by another (donor kinase) 19 . The interface of this asymmetric dimer has been defined crystallographically and by mutagenesis and involves the N-terminal lobe (including Ile706) of the acceptor kinase and the C-terminal lobe (including Val948) of the donor kinase 19 . A peptide segment (segment 1) of the tumor suppressor protein MIG6 (RALT) has been shown to be a moderately potent inhibitor of EGFR kinase activity by binding to the C-lobe of the EGFR kinase domain and sterically blocking asymmetric dimer formation 20 (Fig. 1b) . Another MIG6 segment C-terminal to segment 1 (segment 2) enhances the inhibitory activity of MIG6 and is believed to interact directly with the EGFR kinase active site 20 .
Previous in vitro studies of the isolated L858R EGFR kinase domain have shown that it is ~50-fold more active relative to the WT kinase domain but does not seem to depend on asymmetric dimer formation 19, 21 . However, the L858R EGFR kinase domain is sensitive to erlotinib and MIG6 inhibition 20, 22 . Tyrosine phosphorylation of MIG6 seems to be greater in cancer cell lines containing ∆746-750 EGFR or L858R EGFR, suggesting that in addition to inhibiting EGFR, MIG6 may also be a direct substrate of these mutant EGFRs 23 . There has been limited enzymologic characterization of the ∆746-750 EGFR kinase domain 24 . Cell-based assays of full-length L858R-and ∆746-750 EGFRs show enhanced autophosphorylation of the EGFR C-terminal tails and other proteins relative to WT EGFR 22, 25, 26 , but the enzymologic basis for this increased phosphorylation has been difficult to establish because of the complex environment of the cell.
Previously, we demonstrated the feasibility of expressing, purifying and analyzing the kinetics for near full-length EGFR (tEGFR, residues 25-1022), which lacks only part of the C-terminal tail 27 . We showed that the EGF-bound form of WT tEGFR had a k cat that was 150-fold greater and a sensitivity to erlotinib that was ~25-fold higher than the cetuximab-bound form, consistent with EGF-driven activation 27 . Notably, and not readily understood on the basis of the kinase crystal structures, the potencies of lapatinib for EGF-and cetuximab-bound tEGFRs were found to be within two-fold of one another 27 . a r t i c l e s To investigate the effects of cancer-associated EGFR mutations on the mechanism and degree of EGFR activation, we here examine the kinase activity of wild-type and mutant EGFRs in the presence and absence of inhibitors targeting different activation states of EGFR. Unexpectedly, we find that EGF-independent activation of L858Rand ∆746-750 tEGFRs remains strongly dependent on asymmetric kinase dimer formation.
RESULTS

Expression and purification of L858R and ∆746-750 tEGFRs
We transiently transfected the cDNAs encoding human EGFR residues 25-1022 (tEGFR) having mutations L858R or ∆746-750 into 2-4 l of HEK 293 GnTi − cells 28 , and purified the mutant tEGFRs from detergent-solubilized cell extracts, as previously described using the anti-EGFR Ab 528 (refs. 27,29) . Expression levels of the mutant tEGFRs were reduced compared to WT tEGFR ( Fig. 1c) , leading us to suspect that the oncogenic forms of tEGFR may be cytotoxic at high expression levels because of excessive kinase activity 30, 31 or unstable because of the mutation. We thus evaluated expression in the presence of the reversible EGFR inhibitor erlotinib, which indeed led to enhanced expression of both mutant tEGFRs at the relatively low inhibitor concentration of 50 nM ( Fig. 1c) . Addition of erlotinib to the cell culture media allowed us to purify ~0.1 mg of L858R tEGFR and ∆746-750 tEGFR per liter of cell culture. We obtained an EGF-bound and a cetuximab Fab-bound form of each tEGFR mutant by eluting the affinity column, with either EGF or the cetuximab Fab. These tEGFR complexes were further treated by size-exclusion chromatography, and the majority of tEGFRs were eluted at positions consistent with the formation of high-molecular-weight-but self-limited-oligomers. We estimated tEGFR purities to be >80% by SDS-PAGE ( Fig. 1d) . We used extensive dialysis and chromatography to remove erlotinib before storage of purified tEGFR. We observed similar ATP K m app and k cat values for two different protein batches purified from cells cultured using either a high (2 µM) or low (50 nM, considerably below the tEGFR IC 50 , vide infra) concentration of erlotinib, indicating that erlotinib was effectively removed during purification.
Kinetic parameters of the mutant tEGFRs
We assayed the mutant tEGFRs by using a direct, radiometric assay in which transfer of phosphate from [γ-32 P]ATP to a biotinylated peptide was monitored after avidin pulldown of radiolabeled phosphopeptide. Both L858R tEGFR and ∆746-750 tEGFR in their EGF-and cetuximabbound forms show linear kinase activity versus time or enzyme concentration ( Supplementary Fig. 1 ), suggesting that these mutant receptors are stable in the conditions of our assay. It is readily apparent from these results that the cetuximab-bound forms of oncogenic mutant tEGFRs are markedly more active than WT enzyme in the presence of cetuximab, which shows poorly detectable kinase activity under similar conditions. The k cat and K m app values for peptide and ATP substrates for WT-and mutant tEGFRs are shown in Table 1 (steadystate curves are shown in Supplementary Fig. 2 ). In the cetuximabbound complexes, we see considerable differences in the k cat values between the oncogenic mutant tEGFRs and WT tEGFR. The k cat values for cetuximab-bound oncogenic tEGFRs are within two-fold of each other but approximately 200-fold greater than the k cat for cetuximabbound WT tEGFR. By contrast, the k cat values for the EGF-bound WT and EGF-bound mutant tEGFRs are similar to each other and to the cetuximab-bound forms of L858R-and ∆746-750 tEGFRs. These results indicate that the activities of oncogenic tEGFRs are comparable to or greater than that of EGF-stimulated WT tEGFR.
The ATP K m values also show marked differences between mutantand WT tEGFRs. Compared to that of the WT EGF-tEGFR complex, III  I   I  I   III  III   II II   IV  IV  II  IV   C-lobe   Tyrosine phosphorylation   Leu858 Val948
Active conformation Inactive conformation Figure 1 Activation and inhibition mechanism for WT EGFR and the expression and purification strategy for mutant tEGFRs. (a) Unliganded and cetuximab-bound WT EGFRs exist primarily in the tethered conformation. EGF binding to the ectodomain initiates formation of a specific receptor-mediated dimer and activation of the intracellular kinase domain through formation of an asymmetric dimer. The active conformation of the kinase domain is depicted as blue and the inactive conformation is depicted as gray. Cetuximab is shown in light blue and the EGF is shown in purple (not to scale). (b) MIG6 inhibits WT EGFR by binding to the C-lobe of the EGFR kinase domain and blocking the asymmetric dimer interface. Sites of crucial residues studied here are indicated. (c) Western-blot analysis of the expression levels of WT-, L858R-and ∆746-750 tEGFRs in the presence or absence of the EGFR inhibitor erlotinib. (d) Coomassie blue-stained SDS-PAGE analysis of the purified L858R tEGFR and ∆746-750 tEGFR, with either EGF or cetuximab (Cetux) as ligand. a r t i c l e s the ATP K m values of the L858R-and ∆746-750 tEGFRs are 50-to 200-fold higher. The elevated ATP K m for L858R tEGFR is consistent with that found in a previously reported analysis of the isolated L858R kinase domain 21, 24 . Because both Leu858 and the 746-750 amino acid loop are distant from the ATP binding site and from each other, the origin of the elevated ATP K m values is not readily apparent from X-ray crystal structures. In contrast to the widely divergent ATP K m values in WT-versus mutant tEGFRs, the effects of the mutations on peptide substrate K m values are less substantial.
However, the L858R mutant shows a three-to four-fold higher peptide K m value versus WT-and ∆746-750 tEGFRs, which may reflect substrate-binding interactions involving the activation loop on which Leu858 resides 19, 32 .
Inhibition of oncogenic tEGFRs by kinase inhibitors
We next examined the ability of the ATP mimic AMP-PNP, as well as the therapeutic agents erlotinib and lapatinib, to inhibit oncogenic tEGFRs. AMP-PNP showed similar IC 50 values for WT-and mutant tEGFRs in the range of 80-200 µM (Supplementary Fig. 3 ). Taking into account the ATP concentration used (10 µM) and the respective tEGFR ATP K m app values, we found the K i values of AMP-PNP to be approximately five-to eight-fold higher for L858R (107 ± 19 µM) and ∆746-750 (160 ± 59 µM) compared to WT (21 ± 5 µM). Although clearly an increase, this five-to eight-fold change is substantially lower than the 50-to 200-fold K m differences for ATP among these EGFR forms, suggesting that the ATP K m differences result mainly from changes in rate-determining steps in catalysis, rather than simply from changes in binding affinities for nucleotide.
The apparent K i values for erlotinib and lapatinib were also measured for each tEGFR mutant ( Table 2 and Supplementary Fig. 4) . The L858R-and ∆746-750 tEGFR forms were potently inhibited by erlotinib, with apparent K i values in the range of 0.1-0.4 µM, about equal to the apparent K i of erlotinib for WT tEGFR complexed with EGF. However, compared to WT tEGFR, the oncogenic mutant tEGFRs showed similar potencies regardless of EGF or cetuximab ligand. In contrast to the behavior of erlotinib, the L858R-and ∆746-750 tEGFR forms were highly resistant to lapatinib, with apparent K i values in the range of 2-6 µM. Taken together, these results suggest a model in which the L858R and ∆746-750 mutations drive tEGFR into an active conformation, resulting in diminished access to the inactive state, even when compared to the EGF-bound WT tEGFR.
MIG6 and tEGFR
The tumor suppressor protein MIG6 contains a 77-amino acid region composed of two functional regions, termed segments 1 and 2 (referred to hereafter as segment (or seg) 1+2), that potently inhibit EGFR kinase activity, partly by binding the C-lobe of the EGFR kinase domain and blocking asymmetric dimer formation 20 . Recent cellular proteomic studies have suggested that this region of MIG6 is also tyrosine phosphorylated in response to EGF 23 . We found that tEGFR efficiently phosphorylates MIG6 segment 1+2 on tyrosine residues (Fig. 2a,b and Supplemental Methods) and that both L858R-and ∆746-750 tEGFRs catalyze the reaction ~10-fold better than WT tEGFR does ( Table 3 and Supplementary Fig. 5) . Notably, the level of autophosphorylation of WT tEGFR in reactions that contained MIG6 segment 1+2 was substantially inhibited relative to the oncogenic tEGFR forms (Fig. 2a) . To more precisely measure the effects of MIG6 inhibition, we investigated the effects of both segment 1 (residues 334-364) and the entire 77-amino acid region (segment 1+2, residues 336-412) of MIG6 upon phosphorylation of our biotinylated EGFR substrate peptide, which could readily be separated from MIG6 by using a streptavidin-containing resin. In prior binding and inhibitory studies on the EGFR catalytic domain, segment 1 of MIG6 was sufficient to bind the C-lobe surface of the kinase domain but bound with ~100-times weaker affinity relative to segment 1+2 (ref. 20) . Segment 1 of MIG6 was a moderate inhibitor of EGF-bound WT tEGFR (IC 50 = 100 µM), whereas L858R-and ∆746-750 tEGFR were essentially resistant to inhibition by segment 1 a r t i c l e s ( Supplementary Fig. 6 ). Segment 1+2 of MIG6 was a considerably more potent inhibitor of EGF-bound WT tEGFR, with an IC 50 of 0.5 µM, similar to its potency versus the isolated EGFR kinase domain ( Fig. 2c) and to the previously determined value versus the L858R EGFR kinase domain 20 . However, MIG6 segment 1+2 showed an IC 50 of ~20 µM versus both L858R tEGFR and ∆746-750 tEGFR (Fig. 2c) . Because the IC 50 of MIG6 segment 1+2 is 0.4 µM for the isolated kinase domain of L858R 20 , the far weaker inhibition of L858R tEGFR by MIG6 segment 1+2 suggests that the C-lobe of the kinase domain in the near full-length mutant protein is much less accessible to MIG6 interaction.
Role of asymmetric dimer in oncogenic tEGFRs
Mutations in the N-lobe (I706Q) or C-lobe (V948R) region of the asymmetric kinase dimer interface have been shown to impair EGFinduced activation of WT EGFR in cells 19, 20 . However, the double mutant L858R V948R in the isolated EGFR kinase domain has been shown to have essentially identical catalytic activity to the isolated L858R EGFR kinase domain, suggesting that dimerization is not important for the constitutive activation of this oncogenic EGFR 20 .
To investigate this issue for tEGFR, we introduced simultaneous L858R and I706Q substitutions into tEGFR and measured their effects on catalytic activity in the presence of EGF (Fig. 3a,b and Supplementary Fig. 2b) . In the presence of EGF, this double mutant tEGFR showed a kinase rate that was about thirty times lower than the single mutant L858R tEGFR but showed a similar ATP K m (Table 1 and Supplementary Fig. 2b) . Notably, in the presence of cetuximab, the kinase rate of L858R I706Q tEGFR was about ten times lower than the EGF-bound form, close to the limit of detection (Fig. 3a,b) . These results suggest that the kinase domain asymmetric dimer interface in L858R tEGFR contributes substantially to its constitutive kinase activity and that EGF can still promote dimerization in the presence of an N-lobe interface mutation.
To exclude the possibility that I706Q was affecting tEGFR kinase activity independently of dimer interface effects, we prepared and analyzed L858R V948R tEGFR. The kinase activities of L858R V948R tEGFR in its EGF-and cetuximab-bound forms were reduced substantially compared to that of L858R tEGFR (Fig. 3a,b) , indicating that mutation of either the N-lobe or C-lobe face of the dimer interface of L858R decreases the catalytic rate by 10 to 30 times. To probe the conformational properties of L858R I706Q tEGFR further, we examined its sensitivity to inhibition by lapatinib (Supplementary Fig. 4b ). As shown in Table 2 , the apparent K i of lapatinib for EGF-bound L858R I706Q tEGFR is 700 nM, about six times lower than the apparent K i of lapatinib for EGF-bound L858R tEGFR. These observations indicate that activation by the L858R substitution is coupled to kinase dimer formation and that inhibiting dimer formation by mutation increases accessibility of the inactive kinase conformation.
Next, we investigated the kinase activity of ∆(746-750) I706Q tEGFR (Fig. 3c) . In the EGF-bound form, ∆(746-750) I706Q tEGFR showed a kinase rate that was five times lower than that of ∆746-750 tEGFR. Kinase activity was further reduced by three times for the cetuximab-bound form of ∆(746-750) I706Q tEGFR, relative to the EGF-bound form. Taken together, these data suggest that the asymmetric dimer interface also remains important for activation of the tEGFR with the 746-to 750-residue loop deletion, although it appears that there is a larger amount of residual kinase activation in ∆(746-750) I706Q tEGFR than in L858R I706Q tEGFR.
DISCUSSION
This study finds that the two most common EGFR mutations in non-small cell lung cancer (L858R and ∆746-750) result in EGFindependent tEGFR activities comparable to, or greater than, the activity of EGF-stimulated WT EGFR, and that tEGFR activation resulting from these mutations remains strongly coupled to asymmetric kinase dimer formation (Fig. 3d) . This model differs from prior enzymatic studies on the isolated L858R EGFR kinase domain 20 that suggested the asymmetric dimer interaction is dispensable for I  III  III   I  I   III   II II   IV  IV   III  I   II  V I  II a r t i c l e s stimulation of catalysis. In contrast to the results for the isolated L858R kinase domain, we observed that mutation of residues in the dimer interface in tEGFR markedly reduced the activity of both the L858R-and ∆746-750 tEGFRs, indicating that this dimerization event is critical for activating both of these oncogenic mutants. Strong resistance to MIG6 inhibition further highlights the loss of accessibility of the asymmetric kinase dimer interface in the purified oncogenic EGFRs, as activation appears to both remain coupled to and drive kinase dimer formation. Size-exclusion chromatography suggests that L858R-and ∆746-750 tEGFR proteins are oligomeric, presumably reflecting chains of tEGFR formed through a series of asymmetric kinase interactions. However, the fact that these mutants did not shift completely to the column void volume suggests that the chains are self-limiting even without the membrane. The thermodynamic interdependency of the active kinase conformation and dimerization provides a plausible model for these results (Fig. 3d) . The previous report that activation is dimer-independent in the isolated EGFR kinase domain underscores the limitations of attempting to understand the regulation of this complex receptor by studying isolated fragments. The multiple domains of full-length EGFR clearly contribute to a web of intra-and intermolecular interactions, including the juxtamembrane region 13, [33] [34] [35] , that couple the effects of activating mutations and dimer formation and are central to the regulation mechanism. The lack of a membrane bilayer and the truncation of the C-tail in our tEGFR studies may have affected the results, but the fact that we recapitulated a high degree of kinase activation for the wild-type EGFR enzyme in its EGF form versus its cetuximab-bound form increases our confidence in the relevance of our findings for the mutant proteins.
The observation that L858R EGFR transfected in cells retains EGF dependency 20, 23 differs from what we found for purified tEGFR. This difference may be a result of the indirect method of measuring kinase activity in cells, EGF effects on cellular trafficking or internalization, or the presence of inhibitory feedback mechanisms that EGF is able to over-ride in cells. In any event, we believe that our data indicating loss of EGF-dependence for L858R mutant reflect the intrinsic properties of the purified oncogenic mutant EGFRs and set a benchmark for analyzing the cellular behavior of these molecules. The presence of heterodimers of oncogenic forms of EGFR with WT EGFR or HER2-4 may also affect the ligand dependency of oncogenic EGFR variants in a cellular context.
The studies reported here also enhance our understanding of the paradoxical inhibitory properties of lapatinib for WT tEGFR in its EGF-and cetuximab-bound forms 27 . We initially interpreted the unexplained parity in potency of lapatinib between the EGF-and cetuximab-bound WT tEGFR forms as potentially due to lapatinib binding favorably in distinct modes to active as well as inactive kinase conformations. Based on the fact that potencies of lapatinib for the L858R-and ∆746-750 tEGFRs were reduced by more than 20 times compared to EGF-bound WT tEGFR, we now hypothesize that the kinase-active conformation of EGF-bound WT EGFR may be nearly isoenergetic with the kinase-inactive state of EGF-bound WT EGFR. In this way, there would be little thermodynamic impediment to lapatinib accessing the kinase-inactive conformation of EGF-bound WT EGFR. Consistent with this model, we found that MIG6 segment 1+2 potently inhibits EGF-bound WT tEGFR, presumably because this asymmetric dimer is not highly stabilized, allowing access of the C-lobe of the kinase domain to efficiently bind segment 1 of MIG6. By contrast, MIG6 segment 1+2 could not effectively inhibit the oncogenic mutant tEGFRs, presumably because the C-lobe is less accessible in conditions that more strongly favor formation of asymmetric kinase dimers.
We also show here that MIG6 is tyrosine phosphorylated by tEGFR, particularly in the L858R-and ∆746-750 forms. These results extend a prior study showing how specific increases in these substrates in isogenic, mutant EGFR tumor cell lines resulted in enhanced tyrosine phosphorylation of MIG6 (ref. 23) . How tyrosine phosphorylation of MIG6 might affect its interaction with EGFR or have other influences in signaling are important questions for future studies. It is also notable that the apparent K m of L858R tEGFR for substrate peptide is ~four-fold greater than the K m values for WT-and ∆746-750 tEGFRs. This difference implies that oncogenic EGFR mutations may affect the specificity or extent of substrate phosphorylation, which we think will be an interesting question for future proteomics studies to address [36] [37] [38] .
Based on the findings here, the marked increase in ATP K m for the L858R-and ∆746-750 tEGFR forms may not only be partially related to altered nucleotide affinities but may also likely result from changes in the microscopic rate constants for the enzymatic transformation. For example, if the chemical (phosphoryl transfer) step for the mutant kinases is greatly accelerated relative to the WT reaction, this rate increase might result in an elevated ATP K m (ref. 39) . From a functional perspective, however, ATP K m values in the 200-700 µM range are of little consequence in the cell because ATP concentrations there are in the millimolar range.
These studies have several implications for cancer therapeutic strategies. Given the resistance of the oncogenic EGFR mutants to lapatinib and cetuximab, there seems to be little rationale for the use of these therapeutic agents in non-small cell lung cancer containing L858R-and ∆746-750 EGFR mutations, whereas the clinical benefit of erlotinib in these cases is readily understood. Furthermore, using MIG6 peptidomimetics to target cancers having these oncogenic mutations could prove challenging, owing to stiff competition for the dimer interface. In future experiments on tEGFRs, we think it will be interesting to determine the effects of the gatekeeper T790M drug-resistant mutation 40 on the relative activation and inhibitor sensitivities of these enzymes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
